Lotilaner ophthalmic solution demonstrates significant efficacy in meta-analysis

Lotilaner ophthalmic solution, at a concentration of 0.25%, shows significant promise as a targeted therapy for treating Demodex blepharitis, according to a systematic review and meta-analysis that examined evidence supporting its efficacy in reducing Demodex mite populations and alleviating ocular surface inflammation associated with the condition.

The study, conducted through a comprehensive literature search in PubMed and the Cochrane Library databases until February 2024, identified 5 relevant trials meeting the inclusion criteria. These trials were then assessed for quality, and a meta-analysis was performed to determine the overall treatment effects of lotilaner ophthalmic solution.

The results revealed significant efficacy of lotilaner ophthalmic solution in various aspects of Demodex blepharitis treatment. This included notable improvements in Collarette Cure, clinically meaningful collarette reduction, achieving at least 1-grade collarette improvement, mite eradication, reduction in mite density, erythema cure, and composite cure when compared to the placebo group.

While the study suggests lotilaner ophthalmic solution as a promising therapeutic option for Demodex blepharitis and associated symptoms, it also notes the presence of high heterogeneity in some outcomes and the need for further research to confirm its effectiveness and safety, particularly in the long term.

Reference
Muhammad Muneeb Akhtar S, Fareed A, Sohaib Asghar M, et al. Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials. Cont Lens Anterior Eye. 2024;102148. doi: 10.1016/j.clae.2024.102148. Epub ahead of print. PMID: 38514290.